Xencor Inc (XNCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xencor Inc (XNCR) has a cash flow conversion efficiency ratio of -0.049x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.82 Million) by net assets ($625.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XNCR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Xencor Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Xencor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xencor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xencor Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jilin Forest
SHG:600189
|
0.056x |
|
Abacus Life Inc.
NASDAQ:ABL
|
-0.075x |
|
Oric Pharmaceuticals Inc
NASDAQ:ORIC
|
-0.078x |
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151
|
N/A |
|
Karoon Energy Ltd
AU:KAR
|
0.165x |
|
Fengfan Power
SHG:601700
|
0.096x |
|
Sheela Foam Limited
NSE:SFL
|
0.038x |
|
Bestlink Tech Co Ltd
SHG:603206
|
-0.067x |
Annual Cash Flow Conversion Efficiency for Xencor Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Xencor Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see XNCR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $674.03 Million | $-202.19 Million | -0.300x | -335.83% |
| 2023-12-31 | $669.13 Million | $85.11 Million | 0.127x | +277.92% |
| 2022-12-31 | $727.50 Million | $24.48 Million | 0.034x | +246.49% |
| 2021-12-31 | $733.50 Million | $-16.85 Million | -0.023x | -162.84% |
| 2020-12-31 | $572.44 Million | $-5.00 Million | -0.009x | -108.06% |
| 2019-12-31 | $593.20 Million | $64.37 Million | 0.109x | +170.98% |
| 2018-12-31 | $521.68 Million | $-79.76 Million | -0.153x | -28.02% |
| 2017-12-31 | $282.05 Million | $-33.68 Million | -0.119x | -139.63% |
| 2016-12-31 | $313.95 Million | $94.62 Million | 0.301x | +83.58% |
| 2015-12-31 | $162.43 Million | $26.67 Million | 0.164x | +145.59% |
| 2014-12-31 | $59.29 Million | $-21.35 Million | -0.360x | -385.61% |
| 2013-12-31 | $73.53 Million | $-5.45 Million | -0.074x | -113.09% |
| 2012-12-31 | $-19.50 Million | $-11.05 Million | 0.567x | +471.26% |
| 2011-12-31 | $-10.94 Million | $-1.08 Million | 0.099x | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more